linjc16/ctgov huggingface dataset:
Iontophoresis With Potassium Iodide and Thyroid Function

Study Overview
=================
Brief Summary
-----------------
The aim of the study: To assess the influence of iontophoresis treatment with 2% potassium iodide on the level of thyroid hormones (TSH, FT3, FT4) The study group: conducting 10 iontophoresis treatments with Potassium iodide; The control group: conducting 10 placebo treatments with iontophoresis with destilled water; Intervention: 10 iontophoresis treatments with 2% potassium iodide in healthy individuals. Test the level of thyroid hormones before and after the 10 iontophoresis treatments; The study allows to assess the influence of iodine on the function of thuroid gland.

Official Title
-----------------
Iontophoresis With Potassium Iodide and the Level of Thyroid Hormones in Healthy Subjects

Conditions
-----------------
Thyroid Dysfunction

Intervention / Treatment
-----------------
* Procedure: Iontophoresis with 2% potassium iodide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy individuals with normal thyroid function Exclusion Criteria: individuals with thyroid disorders, taking thyroid medication, using drugs, alcohol, cigaretttes

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 10 iontophoresis treatments with potassium iodide<br> | Procedure: Iontophoresis with 2% potassium iodide<br>* 10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)<br>|
| No Intervention: 10 iontophoresis treatments with placebo<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the level of thyroid gland hormones (TSH, FT3, FT4) | to test thyroid hormones before and after 10 iontophoresis treatments | change in the thyroid hormones level from the baseline to 14 days after the last treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Iontophoresis, potassium iodine, thyroid
Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to appreciate the influence of renal failure progression on vasculopathy (coronary calcifications and left ventricular hypertrophy) and cardiovascular risk factors.

Detailed Description
-----------------
The aim of this study is to appreciate the relationship between: extension of coronary calcifications and chronic renal failure progression extension of coronary calcifications and levels of osteoprotegerin (bone disease marker) cardiovascular risk factors and coronary calcifications cardiovascular risk factors and existence of cardiovascular diseases

Official Title
-----------------
Vascular Risk Factors and Coronary Calcifications in Chronic Renal Failure Patients: Identification of Specific Factors Linked to Renal Failure Progression

Conditions
-----------------
Chronic Renal Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who has signed the written consent form Patient aged > 18 and < 90 years Chronic renal failure defined by glomerular filtration rate (GFR) group 1: GFR >90 mL/min with urinary biological abnormalities and GFR comprised between 90 and 60 mL/min group 2: GFR comprised between 60 and 30 mL/min group 3: GFR <30 mL/min but without dialysis therapy Exclusion Criteria: Chronic renal failure patient requiring dialysis therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| description of osteoprotegerin levels according to chronic renal failure progression |  | inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| calcium score description according to chronic renal failure progression |  | inclusion | 
| osteoprotegerin description according to calcium score |  | inclusion | 
| relationship between cardiovascular risk factors and calcium score |  | inclusion | 
| relationship between cardiovascular risk factors and cardiovascular disease |  | inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic renal failure, Vasculopathy, Cardiovascular risk, Chronic renal failure patients
Long-Term Effect of Soy Consumption on Cardio-Renal Indices and CRP in Type 2diabetes With Nephropathy

Study Overview
=================
Brief Summary
-----------------
we conducted a longitudinal 4-year clinical trial to determine the long-term effects of soy consumption on lipid profiles, renal-function indices and CRP level among type 2 diabetic patients with nephropathy.

Detailed Description
-----------------
Background: Several short-term trials on the effect of soy consumption on cardiovascular risks are available, but little evidence exists regarding the impact of long-term soy protein consumption among type 2 diabetic patients with nephropathy. Objectives: To determine the effects of long-term soy consumption on cardiovascular risks, C-reactive protein and kidney-function indices among type 2 diabetic patients with nephropathy. Design: This longitudinal randomized clinical trial was conducted among 41 type 2 diabetic patients with nephropathy (18 men and 23 women). Twenty patients in soy protein group consumed a diet containing 0.8 g protein/kg body weight (35% animal proteins, 35% textured soy protein, and 30% vegetable proteins) and 21 patients in control group consumed a similar diet containing 70% animal proteins and 30% vegetable proteins for 4-years.

Official Title
-----------------
Soy-Protein Intake, Cardio-Renal Indices and C-Reactive Protein in Type 2 Diabetes With Nephropathy: a 4-y Randomized Clincal Trial

Conditions
-----------------
Kidney Transplantation

Intervention / Treatment
-----------------
* Dietary Supplement: Soy protein


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes with Nephrophaty Exclusion Criteria: Dialysis Transplantation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Dietary Supplement: Soy protein<br>* 35 % of protein from soy protein for 4-years<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality or using dialysis |  | 4-years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Soy, Diabetes, Nephropathy
The Effect of the Abdominal Corset on Colonoscopy

Study Overview
=================
Brief Summary
-----------------
In patients with central obesity, the effect of the abdominal corset on colonoscopy completeness, cecum and ileum intubation time will be investigated.

Official Title
-----------------
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Conditions
-----------------
Colonoscopy, Complete Colonoscopy, Cecum Intubation Time, İleum Intubation Time

Intervention / Treatment
-----------------
* Device: Abdominal Corset


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Above 18 years, Meeting the central obesity criteria Cases where colonoscopy is performed under elective conditions Exclusion Criteria: In case of emergency, The process is terminated due to bad bowel preparation, Inflammatory bowel disease, Serious arrhythmia, Chronic obstructive pulmonary disease Coronary artery disease The previous abdominal surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Standard method group | Device: Abdominal Corset<br>* The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.<br>|
| Group 2<br>Abdominal corset group | Device: Abdominal Corset<br>* The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central Obesity | BMI ≥ 30 (kg / m2), waist circumference> 102 cm in men and waist circumference> 88 cm in women | 01/04/2017- 01/06/2017 | 
| Cecum intubation time | Insertion time of the colonoscope from anus to the cecum (second) | 01/04/2017- 01/06/2017 | 
| İleum intubation time | Insertion time of the colonoscope from cecum to the ileum (second) | 01/04/2017- 01/06/2017 |
The Setting and Effect Evaluation of QT in NICU

Study Overview
=================
Brief Summary
-----------------
In order to create a better environment for growth and development for very low birth weight infants(VLBWIs), investigators introduce quiet time, which is an intervention method that reduces environmental noise in the ward and centralizes medical and nursing operations. By analyzing the weight gain of VLBWIs in the intervention group and the control group during hospitalization, the effect of setting a quiet time in the NICU on improving the growth and development of VLBWIs is evaluated.

Official Title
-----------------
The Setting and Effect Evaluation of Quiet Time in Neonatal Intensive Care Unit

Conditions
-----------------
Very Low Birth Weight Infant

Intervention / Treatment
-----------------
* Other: Quiet time care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Birth weight <1500g; Admit within 24 hours of birth; The guardian signs the informed consent. Exclusion Criteria: Newborn with severe congenital malformations or various chromosomal diseases, genetic metabolic diseases, severe neurological diseases; Newborn who do not achieve discharge or death at the end of the study period.

Ages Eligible for Study
-----------------
Maximum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Quiet time care<br>Reduce noise and centralize medical or nursing operations in the NICU | Other: Quiet time care<br>* This study is a non-self before and after control study. The data of VLBWIs in the control group is collected in the early stage, and the quiet time intervention is carried out in the later period, and the data of VLBWIs in the intervention group is collected<br>|
| No Intervention: Routine nursing care<br>Perform routine nursing care for the VLBWIs in the NICU | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean weekly gain in weight of VLBWIs | The average weekly gain in weight of VLBWIs in the intervention group minus the average weekly gain in weight of VLBWIs in the control group | From the day the VLBWI admitted to the day VLBWI discharged, about two months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quiet Time, Weight
Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)

Study Overview
=================
Brief Summary
-----------------
Cystic lesions of the pancreas are frequent with a risk of degeneration into adenocarcinoma with pejorative prognosis. IPMNs require characterization to clarify their potential for degeneration. Clinical and morphological risk factors for degeneration determine the monitoring rate and the indication for pancreatic surgery. Pancreatic surgery remains invasive with high morbidity and mortality rates.

Detailed Description
-----------------
This is a monoservice and monocentric retrospective study at the Nancy CHRU. We will study the risk factors for IPMNs degeneration in order to determine the most sensitive and specific. To do this, we will use high-grade dysplasia or invasive cancer on the histological analysis of surgical specimens as the primary endpoint. The study population will be patients with Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between September 2009 and October 2021.

Official Title
-----------------
Sensitivity and Specificity Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)

Conditions
-----------------
Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU

Intervention / Treatment
-----------------
* Behavioral: Sensitivity and specificity of risk factors for degeneration of IPMNs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between September 2009 and October 2021, adults and without legal protection measures Exclusion Criteria: IPMNs not operated Pancreatic cancer without IPMNs Patients whose state of health contraindicates pancreatic surgery Non-adult patient Patients under legal protection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Sensitivity and specificity of risk factors for degeneration of IPMNs|Measurement of high-grade dysplasia or invasive cancer on the histological analysis of the surgical specimen|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| High-grade dysplasia or invasive cancer | High-grade dysplasia or invasive cancer on histological analysis of the surgical specimen | 12 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IPMNs, Intraductal Papillary Mucinous Neoplasms
Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.

Detailed Description
-----------------
Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be performed at every visit. Patients will be compensated for time and travel.

Official Title
-----------------
The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Conditions
-----------------
Rhinitis

Intervention / Treatment
-----------------
* Drug: montelukast
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 - 65 years Diagnosed with NARES Exclusion Criteria: Smokers, exposed to passive smoke Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or vasomotor rhinitis (VMR)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>montelukast | Drug: montelukast<br>* 10mg<br>* Other names: Singulair;|
| Placebo Comparator: 2<br>placebo | Drug: placebo<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine whether montelukast is more effective than placebo at reducing the number of nasal eosinophils associated with NARES |  | December 2008 | 
| Determine whether montelukast is more effective than placebo at reducing nasal symptom scores |  | December 2008 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NARES, eosinophils, nasal symptoms
Management of Skin Graft Donor Site Wound in Aged Patient

Study Overview
=================
Brief Summary
-----------------
The complication of donor site in skin grafting often acts as a causing factor for extended treatment period. The elderly individuals tend to be afflicted by impaired wound healing. Herein, the investigators presented the outcome of skin regrafting in the elderly patients.

Official Title
-----------------
Management of Skin Graft Donor Site Wound in Aged Patient

Conditions
-----------------
Skin Regrafting; Donor Site of Skin Grafting; Vancouver Scar Scale

Intervention / Treatment
-----------------
* Procedure: skin graft
* Procedure: no skin graft


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patient who need to perform skin grafting surgery Exclusion Criteria: All patient who cannot be half or general anesthetized severe comorbidities

Ages Eligible for Study
-----------------
Minimum Age: 60 Months
Maximum Age: 99 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: skin graft<br> | Procedure: skin graft<br>* In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation<br>|
| Placebo Comparator: no skin graft<br> | Procedure: no skin graft<br>* In the experimental group, the operative plan was to consider taking a 15% larger amount than necessary and replace over-harvested skin back onto the donor site in an island manner. Any remaining skin graft was returned to the donor site and a polyurethane dressing [Alleyvn, Smith, & Nephew] was placed on the regrafted skin for fixation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| healing time |  | three months |
Study of Retinal Vascular Changes After Ocular Blunt Trauma

Study Overview
=================
Brief Summary
-----------------
This study evaluates the retinal vascular features using optical coherence tomography angiography in patients that received ocular blunt trauma.

Detailed Description
-----------------
To investigate, using optical coherence tomography angiography, early retinal vascular features 48 hours after ocular trauma and to detect their changes during 6 months' follow up. The optical coherence tomography angiography represents a novel and noninvasive diagnostic technique that allows a detailed analysis of retinal vascular features.

Official Title
-----------------
Retinal Vascular Features in Ocular Blunt Trauma by Optical Coherence Tomography Angiography

Conditions
-----------------
Ocular Injury

Intervention / Treatment
-----------------
* Diagnostic Test: Optical Coherence Tomography Angiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age older than 40 years diagnosis of previous ocular blunt trauma absence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. absence of significant lens opacities, low-quality OCT and OCT-A images. Exclusion Criteria: age younger than 40 years absence of previous ocular blunt trauma presence of previous ocular surgery, congenital eye disease, high myopia (>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. presence of significant lens opacities, low-quality OCT and OCT-A images.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with ocular blunt trauma<br>Patients with previous ocular blunt trauma in one eye. | Diagnostic Test: Optical Coherence Tomography Angiography<br>* Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)<br>|
| Control Group<br>Healthy fellow eyes without actual and previous ocular trauma | Diagnostic Test: Optical Coherence Tomography Angiography<br>* Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The measurements of retinal vessel density in patients after ocular blunt trauma during 6 months's follow up | To evaluate the changes in retinal vessel density in 18 patients, at baseline and 1, 3, 6 months after ocular blunt trauma, using optical coherence tomography angiography. The parameter analyzed by optical coherence tomography angiography was: retinal vessel density | Six months |